Shilpa Medicare’s stock surged by 3.87% to ₹917 on the NSE at 9:22 AM after Antique Stock Broking initiated a ‘Buy’ rating with a target price of ₹1300. The firm cited Shilpa Medicare’s strong formulation pipeline, driven by its Novel Drug Delivery System (NDDS), with key launches lined up for FY25 and FY26.
Antique highlighted that Shilpa Medicare is entering a new growth phase, fueled by sustainable revenue from finished dosage formulations (FDF), active pharmaceutical ingredients (API), and an expected major expansion in its contract development and manufacturing organization (CDMO) business. With the company’s aggressive capex cycle now behind it, analysts predict a revenue CAGR of 34% over the next two years, along with an EBITDA margin of 35% by FY27 and an EPS CAGR of over 100% on a low base.
The stock’s jump reflects investor optimism in the company’s robust pipeline and promising growth prospects for the coming years.
